PT  - JOURNAL ARTICLE
AU  - Chun, June Young
AU  - Baek, Gyuseung
AU  - Kim, Yongdai
TI  - Transmission onset distribution of COVID-19
AID  - 10.1101/2020.05.13.20101246
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.13.20101246
4099  - http://medrxiv.org/content/early/2020/07/23/2020.05.13.20101246.short
4100  - http://medrxiv.org/content/early/2020/07/23/2020.05.13.20101246.full
AB  - Objectives The distribution of the transmission onset of COVID-19 relative to the symptom onset is a key parameter for infection control. It is often not easy to study the transmission onset time, as is difficult to know who infected whom exactly when.Methods We inferred transmission onset time from 72 infector-infectee pairs in South Korea, either with known or inferred contact dates by means of incubation period. Combining this data with known information of infector’s symptom onset, we could generate the transmission onset distribution of COVID-19, using Bayesian methods. Serial interval distribution could be automatically estimated from our data.Results We estimated the median transmission onset to be 1.31 days (standard deviation, 2.64 days) after symptom onset with peak at 0.72 days before symptom onset. The pre-symptomatic transmission proportion was 37% (95% credible interval [CI], 16–52%). The median incubation period was estimated to be 2.87 days (95% CI, 2.33–3.50 days) and the median serial interval to be 3.56 days (95% CI, 2.72–4.44 days).Conclusions Considering the transmission onset distribution peaked with the symptom onset and the pre-symptomatic transmission proportion is substantial, the usual preventive measure might be too late to prevent SARS-CoV-2 transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Cancer Center (NCC2020-0119)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code and data are available in the supplementary material.